HK Stock Market Move | RIBOLIFE-B (06938) rose nearly 5% as its mid-term performance achieved profitability and continued to improve. The extrahepatic technology is expected to lead the next generation of blue ocean.

RIBOLIFE-B (06938) rose nearly 5%, and as of the time of writing, it was up 4.89% to HKD 63.3, with a transaction amount of HKD 10.46 million. In terms of news, recently, RIBOLIFE-B disclosed its mid-term performance for 2026. The company achieved a revenue of RMB 420 million, a year-on-year increase of 304%; during the period, the net profit was RMB 23 million, marking a turnaround from loss, with cash and cash equivalents at RMB 2.24 billion at the end of the period. The improvement in performance is mainly attributed to the recognition of licensing income related to global collaboration projects and the continued advancement of collaboration milestones. At the same time, the company continues to maintain investment in R&D for its core clinical pipeline and innovative delivery platform. The report titled "RIBOLIFE-B (06938) Mid-term Results for 2026: Global Collaborations Drive Revenue Growth, Core Pipeline and Platform Value Continue to Materialize" points out that in the first half of 2026, the innovative platform capabilities developed by Ribo Bio were highly recognized by leading multinational pharmaceutical companies both domestically and internationally, achieving consecutive R&D milestones, which further validated the company's ability to continuously produce globally valuable innovative assets. As the application of siRNA drugs gradually expands from targeting the liver to extrahepatic tissues, delivery capability is becoming an important technical competitive direction for the next stage of the industry. Ribo Bio has established multiple extrahepatic delivery technology directions around the kidneys, myocardium, adipose tissue, and central nervous system, with the first renal-targeting project having entered the IND-enabling stage.